Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

IMV Inc. (IMV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5225-0.0792 (-13.16%)
At close: 04:00PM EDT
0.5257 +0.00 (+0.61%)
After hours: 04:49PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close0.6017
Open0.6200
Bid0.5300 x 1000
Ask0.5250 x 1000
Day's Range0.5225 - 0.6200
52 Week Range0.4600 - 1.9100
Volume82,097
Avg. Volume168,953
Market Cap46.424M
Beta (5Y Monthly)1.76
PE Ratio (TTM)N/A
EPS (TTM)-0.5160
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.85
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IMV

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • IMV Inc.
    Daily – Vickers Top Buyers & Sellers for 09/28/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Business Wire

    IMV Provides an Update on The VITALIZE Trial

    DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass., September 30, 2022--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today provided an update on the open-label VITALIZE study evaluating its lead product maveropepimut-S (MVP-S) in combination with pembrolizumab and intermittent low-dose cyclophosphamide (CPA) in patients with relapses, refractory di

  • Business Wire

    IMV Inc. Announces Strategic Reorganization

    DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., September 15, 2022--IMV Inc. (Nasdaq: IMV; TSX: IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and hematologic cancers, today announced a strategic reorganization together with the appointment of Dr. Saman Maleki to the Company’s Board of Directors and promotion of Brittany Davison to Chief Accounting Officer.

  • Business Wire

    IMV Inc. to Present at Two Investor Conferences in September

    DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass., September 01, 2022--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that members of IMV’s executive management team will be presenting at two investor conferences in September. Please find additional details on the conferences below.

Advertisement
Advertisement